Inhibikase Grants 981,243 Options at $2.03 Exercise Price to Seven Hires
IKT•Inhibikase granted non-qualified options for 981,243 shares to seven new non-executive hires under its 2026 Inducement Equity Plan, effective June 30, 2026. The options carry a $2.03 exercise price, ten-year term, and vest 25% after one year with the balance in 36 equal monthly installments.
1. 2026 Inducement Equity Plan Grants
Inhibikase approved inducement grants under Nasdaq Listing Rule 5635(c)(4), issuing non-qualified stock options for up to 981,243 shares of common stock to seven newly hired non-executive employees. These grants became effective June 30, 2026 and were authorized by the Compensation Committee to attract key talent.
2. Exercise Price and Vesting Schedule
Each option carries an exercise price of $2.03, equal to the closing share price on the effective date, and a ten-year term. Vesting is structured with 25% of options exercisable after one year, and the remaining 75% vesting in 36 equal monthly installments thereafter.
3. Potential Dilutive Impact
If fully exercised, the 981,243 shares would increase the company’s outstanding share count, potentially diluting existing shareholders. The timing of exercises will depend on employee decisions as vesting milestones are reached over the next four years.
